XENON PHARMACEUTICALS INC. Current Liabilities
XENON PHARMACEUTICALS INC. (XENE) had Current Liabilities of $45.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $45.01M.
- 2026-03-31: Liabilities, Current $39.81M.
- 2025-12-31: Liabilities, Current $41.79M.
- 2025-09-30: Liabilities, Current $38.34M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $45.01M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $39.81M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $41.79M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $38.34M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $33.05M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $32.03M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $35.59M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $29.70M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $31.29M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $22.22M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $27.27M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $24.74M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $28.16M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $22.49M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $22.70M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $15.54M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $13.74M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $7.98M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $14.32M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $12.86M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $14.98M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $11.49M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $14.78M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $16.92M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $21.05M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $48.52M 10-Q/A · filed 2020-05-26 | |
| 2019-12-31 | $43.38M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $11.70M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $9.33M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $6.38M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.12M 10-K · filed 2020-03-09 | |
| 2018-09-30 | $4.41M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $3.09M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $3.79M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $4.08M 10-K · filed 2019-03-06 | |
| 2016-12-31 | $3.59M 10-K · filed 2018-03-07 | $3.52M 10-K · filed 2017-03-08 |
| 2016-09-30 | $3.98M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $2.93M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $2.87M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $2.78M 10-K · filed 2017-03-08 | |
| 2015-09-30 | $5.34M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $12.02M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $16.55M 10-Q/A · filed 2015-08-13 | $10.25M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $14.29M 10-K · filed 2016-03-08 | |
| 2014-09-30 | $16.34M 10-Q · filed 2014-12-15 | |
| 2013-12-31 | $18.20M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |